NCT02250170View on ClinicalTrials.gov

Safety and Biomarker of OPB-111077 in Subjects With Advanced Solid Tumor

PHASE1CompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

October 23, 2014

Primary Completion Date

March 8, 2019

Study Completion Date

March 8, 2019

Conditions
Solid Tumor
Interventions
DRUG

OPB-111077

Tablet, Oral, 300mg/500mg/700mg/900mg 4 days-on \& 3 days-off (21 days=1cycle)

Trial Locations (3)

Unknown

Asan Medical Center, Seoul

Seoul National University Bundang Hospital, Seoul

Seoul National University Hospital, Seoul

Sponsors
All Listed Sponsors
collaborator

Otsuka Pharmaceutical Co., Ltd.

INDUSTRY

lead

Korea Otsuka Pharmaceutical Co., Ltd.

INDUSTRY